San Diego, California, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reports that the shareholders of Emerald Health Therapeutics, Inc. ("Emerald" or the "Company") (CSE: EMH; OTCQB: EMHTF) today approved the proposed plan of arrangement (the "Arrangement") with Skye, with approval by 87.07% of votes cast by shareholders for that resolution. The Arrangement resolution also received majority of the minority approval, excluding interested parties, pursuant to applicable law.

Originally posted here:
Skye Bioscience Reports that Emerald Health Therapeutics Shareholders Voted in Favor of Plan of Arrangement with Skye

NEWS RELEASE - REGULATED INFORMATIONAugust 19, 2022, 4:00 PM EDT / 22:00 CET

Read this article:
Mdxhealth's New Share Capital Amount and New Number of Shares

ARLINGTON, Mass., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

Visit link:
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

OSLO, Norway, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced it will report its financial results for the first half of 2022 on August 24, 2022 before market open and subsequently host a webcast presentation at 4 p.m. CET / 10 a.m. ET.

View original post here:
Nykode Therapeutics to announce financial results for the first half of 2022 and host webcast presentation on August 24, 2022

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

Read the original:
ObsEva Receives Nasdaq Non-Compliance Notice

Seasoned pharmaceutical industry executive to lead Tessa’s corporate and development strategy built around its proprietary autologous and allogeneic CAR-T platforms

See the rest here:
Tessa Therapeutics Appoints Thomas Willemsen as President and CEO

Basel, Switzerland, August 22, 2022. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today announced the signing of an agreement with YA II PN, Ltd, an exempted company incorporated in the Cayman Islands with limited liability, a company of the group of companies managed by Yorkville Advisors Global LP, its investment manager ("Yorkville"), for a financing via the issuance of convertible notes of up to CHF 20 million, to be drawn in tranches.

Continued here:
Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville

Pratteln, Switzerland, and Rockville, MD, USA, August 22, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the first patient has been dosed in a Phase 2 pilot study to assess vamorolone in Becker muscular dystrophy (BMD), funded by the U.S. Food and Drug Administration (FDA).

Link:
Santhera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy

Basel, Switzerland, 22 August 2022 -- Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today announced it will host a virtual event on the use of KIN001 for the treatment of COVID-19 on Wednesday, August 24 at 2:00 pm CET.

See the original post:
Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19

DXS INTERNATIONAL PLC

See original here:
Annual Financial Report